| Similar Articles |
|---|
 |
Chemistry World
January 13, 2011
Andrew Turley |
UK tilts towards appraisal of Avastin as eye drug The UK is moving closer to opening up the National Health Service to cancer drug Avastin (bevacizumab) for the treatment of eye conditions, such as age-related macular degeneration.   |
Chemistry World
September 24, 2014
Phillip Broadwith |
Review says cheaper drug is safe for eye disease Researchers have added weight to the argument that health services should use the cancer drug Avastin (bevacizumab) to treat age-related wet macular degeneration, instead of the more expensive Lucentis (ranibizumab). |
Chemistry World
April 2, 2015
Emma Stoye |
Novartis accused of 'derailing' trials for cheap eye disease drug The British Medical Journal has accused pharmaceutical giant Novartis of deliberately hindering research into the use of anticancer drug Avastin (bevacizumab) to treat age-related wet macular degeneration. |
The Motley Fool
November 19, 2011
Luke Timmerman |
Regeneron Wins FDA Approval for Macular-Degeneration Drug The company can begin selling Eylea, which treats the leading cause of blindness in the elderly. |
The Motley Fool
May 24, 2005
Charly Travers |
Genentech Eyes a New Market Will Lucentis be the next addition to the biotech giant's growing drug portfolio? Investors, take note. |
Managed Care
August 2006
Thomas Morrow |
New Injectable Medication Effective Against Wet AMD Age-related macular degeneration is the most common cause of blindness in people over age 55. This market will expand rapidly. Managed care should remain informed and start to manage this area. |
The Motley Fool
October 2, 2007
Brian Orelli |
Regeneron Sees Positive Phase 2 Data Regeneron Pharmaceuticals and partner Bayer HealthCare see a bright future for their age-related macular degeneration treatment after announcing positive phase 2 data. |
The Motley Fool
August 21, 2008
Brian Lawler |
Regeneron's Results Clearing Up The drugmaker presents new data on a compelling candidate for macular degeneration treatment. |
The Motley Fool
March 31, 2008
Brian Lawler |
A Good Mix for QLT QLT takes one step closer toward a winning combination for those who suffer from macular degeneration. |
Managed Care
March 2005
Thomas Morrow |
Aptamers: Slowing Progression of AMD A single strand of nucleic acid may hold the key to treating the leading cause of severe vision loss and blindness resulting from age-related macular degeneration. |
BusinessWeek
August 16, 2004
Arlene Weintraub |
The Race to Stop an Eyesight Stealer No magic bullet yet, but new drugs to fight age-related macular degeneration are near. |
Chemistry World
May 21, 2014
Phillip Broadwith |
Novartis enhances its focus with eyecare deal Swiss pharma major Novartis is continuing its quest to excel in a few specialist fields by licensing rights to US firm Ophthotech's lead candidate, Fovista, for wet age-related macular degeneration. |
Chemistry World
June 3, 2014
Phillip Broadwith |
Drug companies rapped for anticompetitive behavior The Italian health ministry is following up on rulings from the country's competition authorities and demanding billions of euros in damages resulting from anticompetitive behavior. |
The Motley Fool
November 22, 2006
Brian Lawler |
How to Market a Drug Too Well Cephalon's promotion of its pain drug Actiq might have crossed the line. |
Pharmaceutical Executive
October 1, 2008
Sarah Houlton |
Open For Debate Tensions mount as stakeholders in the UK health industry attempt to work out drug cost problems. |
The Motley Fool
April 29, 2011
Cindy Johnson |
Regeneron Pharmaceuticals Shares Plunged: What You Need to Know Regeneron Pharmaceuticals dropped 12% in intraday trading today after an analyst at RBC Capital downgraded the stock from outperform to sector perform. |
The Motley Fool
January 3, 2005
Rich Duprey |
Eying Profits in Eye Sight Macular degeneration is proving to be a field with eye-popping potential. Manufactured by Pfizer and Eyetech, a tiny biotech that went public early last year, Macugen was recently approved by the FDA. |
Pharmaceutical Executive
August 1, 2008 |
Harbingers of Change The pharmaceutical industry is changing. Here are eight seminal events that describe how. |
